Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Developmental Remodeling of Thalamic Interneurons Requires Retinal Signaling.

Charalambakis NE, Govindaiah G, Campbell PW, Guido W.

J Neurosci. 2019 May 15;39(20):3856-3866. doi: 10.1523/JNEUROSCI.2224-18.2019. Epub 2019 Mar 6.

2.

Postnatal development of cholinergic input to the thalamic reticular nucleus of the mouse.

Sokhadze G, Campbell PW, Guido W.

Eur J Neurosci. 2019 Apr;49(8):978-989. doi: 10.1111/ejn.13942. Epub 2018 Jul 21.

PMID:
29761601
3.

Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.

Padovan-Neto FE, Sammut S, Chakroborty S, Dec AM, Threlfell S, Campbell PW, Mudrakola V, Harms JF, Schmidt CJ, West AR.

J Neurosci. 2015 Apr 8;35(14):5781-91. doi: 10.1523/JNEUROSCI.1238-14.2015.

4.

Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

Accurso FJ, Van Goor F, Zha J, Stone AJ, Dong Q, Ordonez CL, Rowe SM, Clancy JP, Konstan MW, Hoch HE, Heltshe SL, Ramsey BW, Campbell PW, Ashlock MA.

J Cyst Fibros. 2014 Mar;13(2):139-47.

5.

AMPA receptor upregulation in the nucleus accumbens shell of cocaine-sensitized rats depends upon S-nitrosylation of stargazin.

Selvakumar B, Campbell PW, Milovanovic M, Park DJ, West AR, Snyder SH, Wolf ME.

Neuropharmacology. 2014 Feb;77:28-38. doi: 10.1016/j.neuropharm.2013.08.036. Epub 2013 Sep 10.

6.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW.

Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8.

7.

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW.

N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.

8.

Improving the care of infants identified through Cystic Fibrosis newborn screening.

Marshall BC, Campbell PW 3rd.

J Pediatr. 2009 Dec;155(6 Suppl):S71-2. doi: 10.1016/j.jpeds.2009.09.004. No abstract available.

PMID:
19914444
9.

A pipeline of therapies for cystic fibrosis.

Ashlock MA, Beall RJ, Hamblett NM, Konstan MW, Penland CM, Ramsey BW, Van Dalfsen JM, Wetmore DR, Campbell PW 3rd.

Semin Respir Crit Care Med. 2009 Oct;30(5):611-26. doi: 10.1055/s-0029-1238919. Epub 2009 Sep 16.

PMID:
19760548
10.

Cystic fibrosis foundation: achieving the mission.

Marshall BC, Penland CM, Hazle L, Ashlock M, Wetmore D, Campbell PW 3rd, Beall RJ.

Respir Care. 2009 Jun;54(6):788-95; discussion 795. Review.

11.

Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, Durie PR, Legrys VA, Massie J, Parad RB, Rock MJ, Campbell PW 3rd; Cystic Fibrosis Foundation.

J Pediatr. 2008 Aug;153(2):S4-S14. doi: 10.1016/j.jpeds.2008.05.005.

12.

Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report.

Comeau AM, Accurso FJ, White TB, Campbell PW 3rd, Hoffman G, Parad RB, Wilfond BS, Rosenfeld M, Sontag MK, Massie J, Farrell PM, O'Sullivan BP; Cystic Fibrosis Foundation.

Pediatrics. 2007 Feb;119(2):e495-518.

PMID:
17272609
13.

Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes.

Campbell PW 3rd, White TB.

J Pediatr. 2005 Sep;147(3 Suppl):S2-5. Review. No abstract available.

PMID:
16202776
14.

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd; Macrolide Study Group.

JAMA. 2003 Oct 1;290(13):1749-56.

PMID:
14519709
15.

Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study.

Maisonneuve P, FitzSimmons SC, Neglia JP, Campbell PW 3rd, Lowenfels AB.

J Natl Cancer Inst. 2003 Mar 5;95(5):381-7.

PMID:
12618503
16.

Communicating science: from the laboratory bench to the breakfast table.

Hendrix MJ, Campbell PW.

Anat Rec. 2001 Aug 15;265(4):165-7.

17.

Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis.

LiPuma JJ, Spilker T, Gill LH, Campbell PW 3rd, Liu L, Mahenthiralingam E.

Am J Respir Crit Care Med. 2001 Jul 1;164(1):92-6.

PMID:
11435245
18.

Wisconsin cystic fibrosis chest radiograph scoring system: validation and standardization for application to longitudinal studies.

Koscik RE, Kosorok MR, Farrell PM, Collins J, Peters ME, Laxova A, Green CG, Zeng L, Rusakow LS, Hardie RC, Campbell PW, Gurney JW.

Pediatr Pulmonol. 2000 Jun;29(6):457-67.

PMID:
10821728
19.

Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis.

Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, Farrell PM.

N Engl J Med. 2000 Mar 23;342(12):851-9.

20.

Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report.

Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, Brunzell C, Campbell PW 3rd, Chesrown SE, Duchow C, Fink RJ, Fitzsimmons SC, Hamilton N, Hirsch I, Howenstine MS, Klein DJ, Madhun Z, Pencharz PB, Quittner AL, Robbins MK, Schindler T, Schissel K, Schwarzenberg SJ, Stallings VA, Zipf WB, et al.

Diabetes Res Clin Pract. 1999 Aug;45(1):61-73. Review. No abstract available.

PMID:
10499886
21.

Use of aerosolized antibiotics in patients with cystic fibrosis.

Campbell PW 3rd, Saiman L.

Chest. 1999 Sep;116(3):775-88. Review. No abstract available.

PMID:
10492286
22.

Comparison of culture and PCR for detection of Burkholderia cepacia in sputum samples of patients with cystic fibrosis.

Whitby PW, Dick HL, Campbell PW 3rd, Tullis DE, Matlow A, Stull TL.

J Clin Microbiol. 1998 Jun;36(6):1642-5.

23.

Effects of pediatrician characteristics on management decisions in simulated cases involving apparent life-threatening events.

Hickson GB, Cooper WO, Campbell PW, Altemeier WA 3rd.

Arch Pediatr Adolesc Med. 1998 Apr;152(4):383-7.

PMID:
9559716
24.

Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening.

Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW 3rd, Phillips JA 3rd.

Am J Hum Genet. 1996 Mar;58(3):617-27.

25.

Teaching about cystic fibrosis carrier screening by using written and video information.

Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW 3rd, Phillips JA 3rd.

Am J Hum Genet. 1995 Jul;57(1):171-81.

26.

Detection of Pseudomonas (Burkholderia) cepacia using PCR.

Campbell PW 3rd, Phillips JA 3rd, Heidecker GJ, Krishnamani MR, Zahorchak R, Stull TL.

Pediatr Pulmonol. 1995 Jul;20(1):44-9.

PMID:
7478781
27.

New developments in pediatric pneumonia and empyema.

Campbell PW 3rd.

Curr Opin Pediatr. 1995 Jun;7(3):278-82. Review.

PMID:
7663614
28.

Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: results of a 3-year study.

Gruber WC, Campbell PW, Thompson JM, Reed GW, Roberts B, Wright PF.

J Infect Dis. 1994 Feb;169(2):241-7.

PMID:
8106759
29.

The cystic fibrosis gene and relationships to clinical status.

Campbell PW 3rd, Phillips JA 3rd.

Semin Respir Infect. 1992 Sep;7(3):150-7. Review.

PMID:
1475539
30.

Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion.

Campbell PW 3rd, Parker RA, Roberts BT, Krishnamani MR, Phillips JA 3rd.

J Pediatr. 1992 Feb;120(2 Pt 1):261-4.

PMID:
1735823
31.

Cystic fibrosis: relationship between clinical status and F508 deletion.

Campbell PW 3rd, Phillips JA 3rd, Krishnamani MR, Maness KJ, Hazinski TA.

J Pediatr. 1991 Feb;118(2):239-41. No abstract available.

PMID:
1993951
32.

Cystic fibrosis treated with heart-lung transplantation: North American results.

Frist WH, Fox MD, Campbell PW, Fiel SB, Loyd JE, Merrill WH.

Transplant Proc. 1991 Feb;23(1 Pt 2):1205-6. No abstract available.

PMID:
1989187
33.

Cystic fibrosis, intravenous antibiotics, and home therapy.

Hammond LJ, Caldwell S, Campbell PW.

J Pediatr Health Care. 1991 Jan-Feb;5(1):24-30.

PMID:
1990112
34.

Parental administration of chemical agents: a cause of apparent life-threatening events.

Hickson GB, Altemeier WA, Martin ED, Campbell PW.

Pediatrics. 1989 May;83(5):772-6.

PMID:
2717293

Supplemental Content

Loading ...
Support Center